Nuron Biotech Inc., a specialty biologics and vaccines company, today announced that it has acquired assets relating to the vaccine HibTITER® (Haemophilus b Conjugate Vaccine (Diphtheria CRM197 Protein Conjugate)) from Wyeth LLC, a wholly owned subsidiary of Pfizer Inc, for the U.S. and many other markets, including Japan and Korea. Financial terms of the sale were not disclosed.
HibTITER is a previously marketed pediatric vaccine that Wyeth LLC discontinued several years ago following a reassessment of its portfolio and priorities and given other available vaccine options. HibTITER was one of the first glycoconjugate technology vaccines for humans on the market and was responsible for greatly reducing the incidence of Hib disease in children. Meningitis vaccines are now part of the CDC Recommended Childhood and Adolescent Immunization Schedule with over 10 million annual doses administered each year in the U.S. alone. Nuron is currently working with the FDA to finalize the re-launch strategy for this vaccine.
"Our senior management team sees significant opportunity for HibTITER and looks forward to re-establishing this life-saving vaccine to help protect our children," commented Shankar Musunuri, PhD, MBA, Chief Executive Officer, Founder, Nuron Biotech. "Nuron has a highly focused product portfolio, and, consequently, we can devote significant attention to educating the medical and regulatory community on the value of this vaccine. We know the medical milestones achieved with HibTITER and recognize both the medical need and relevance of this vaccine in the U.S. and markets around the world."
The path to a better tuberculosis vaccine runs through Montana